Biotech raises $42 million to run Huntington’s disease trial
WHY IT MATTERS
This funding enables Latus Bio to move forward with testing their Huntington's disease treatment in patients, which could lead to new therapeutic options for people currently living with limited treatment choices.
A biotech company called Latus Bio has raised $42 million in funding to support a clinical trial for Huntington's disease. This money will help them test a new treatment approach in patients with this genetic brain disorder. The funding shows that researchers are actively working on new ways to help people with Huntington's disease.
Latus Bio 2026-05 04 STAT Article The post Biotech raises $42 million to run Huntington’s disease trial first appeared on Huntington's Disease Society of America . <p>The post Biotech raises $42 million to run Huntington’s disease trial first appeared on Huntington's Disease Society of America .</p>